This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Stromnes, I. M. et al. T cells engineered against a native antigen can surmount immunologic and physical barriers to treat pancreatic ductal adenocarcinoma. Cancer Cell 28, 638–652 (2015)
Rights and permissions
About this article
Cite this article
Flemming, A. Engineered T cells gain access to pancreatic tumours. Nat Rev Drug Discov 15, 16–17 (2016). https://doi.org/10.1038/nrd.2015.40
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2015.40